Literature DB >> 10770781

MICs of oxazolidinones for Rhodococcus equi strains isolated from humans and animals.

T L Bowersock1, S A Salmon, E S Portis, J F Prescott, D A Robison, C W Ford, J L Watts.   

Abstract

Eperezolid and linezolid are representatives of a new class of orally active, synthetic antimicrobial agents. The in vitro activity values (MICs) of linezolid, eperezolid, and comparator antibiotics against 102 strains of Rhodococcus equi isolated from humans and animals were determined. Linezolid was more active than eperezolid against the strains tested; premafloxacin was the most active comparator antibiotic.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10770781      PMCID： PMC89874          DOI： 10.1128/AAC.44.5.1367-1369.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

Review 1.  Clinical manifestations, diagnosis, treatment, and prevention of Rhodococcus equi infections in foals.

Authors:  S Giguère; J F Prescott
Journal:  Vet Microbiol       Date:  1997-06-16       Impact factor: 3.293

2.  Rhodococcus equi infection in HIV-infected patients.

Authors:  A Donisi; M G Suardi; S Casari; M Longo; G P Cadeo; G Carosi
Journal:  AIDS       Date:  1996-04       Impact factor: 4.177

Review 3.  Rhodococcus equi pneumonia in patients infected with the human immunodeficiency virus. Report of 2 cases and review of the literature.

Authors:  J A Capdevila; S Buján; J Gavaldà; A Ferrer; A Pahissa
Journal:  Scand J Infect Dis       Date:  1997

4.  In vitro activity of premafloxacin, a new extended-spectrum fluoroquinolone, against pathogens of veterinary importance.

Authors:  J L Watts; S A Salmon; M S Sanchez; R J Yancey
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

Review 5.  Rhodococcus equi infection in patients with AIDS.

Authors:  M Drancourt; E Bonnet; H Gallais; Y Peloux; D Raoult
Journal:  J Infect       Date:  1992-03       Impact factor: 6.072

6.  In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.

Authors:  G E Zurenko; B H Yagi; R D Schaadt; J W Allison; J O Kilburn; S E Glickman; D K Hutchinson; M R Barbachyn; S J Brickner
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

7.  In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones.

Authors:  R N Jones; D M Johnson; M E Erwin
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

8.  In-vitro susceptibility to antimicrobial drugs of bacterial isolates from horses in The Netherlands.

Authors:  J M Ensink; B van Klingeren; D J Houwers; W R Klein; A G Vulto
Journal:  Equine Vet J       Date:  1993-07       Impact factor: 2.888

9.  Distribution and antimicrobial susceptibility of Rhodococcus equi from clinical specimens.

Authors:  M M McNeil; J M Brown
Journal:  Eur J Epidemiol       Date:  1992-05       Impact factor: 8.082

10.  Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721.

Authors:  A M Slee; M A Wuonola; R J McRipley; I Zajac; M J Zawada; P T Bartholomew; W A Gregory; M Forbes
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191
View more
  8 in total

1.  In vitro activities of linezolid against multiple Nocardia species.

Authors:  B A Brown-Elliott; S C Ward; C J Crist; L B Mann; R W Wilson; R J Wallace
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

2.  In vitro susceptibilities of Rhodococcus equi and other common equine pathogens to azithromycin, clarithromycin, and 20 other antimicrobials.

Authors:  Stephanie S Jacks; Steeve Giguère; An Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

3.  Mutant selection window and characterization of allelic diversity for ciprofloxacin-resistant mutants of Rhodococcus equi.

Authors:  Hidekazu Niwa; Brent A Lasker
Journal:  Antimicrob Agents Chemother       Date:  2010-05-24       Impact factor: 5.191

4.  In vitro activity of PNU-100766 (linezolid), a new oxazolidinone antimicrobial, against Nocardia brasiliensis.

Authors:  L Vera-Cabrera; A Gómez-Flores; W G Escalante-Fuentes; O Welsh
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

5.  Clinical update on linezolid in the treatment of Gram-positive bacterial infections.

Authors:  Sally Ager; Kate Gould
Journal:  Infect Drug Resist       Date:  2012-06-25       Impact factor: 4.003

6.  A Case of Recurrent Meningitis Caused by Rhodococcus species Successfully Treated with Antibiotic Treatment and Intrathecal Injection of Vancomycin through an Ommaya Reservoir.

Authors:  Kanglok Lee; Min Rho; Miyeon Yu; Joohee Kwak; Seungpyo Hong; Jisoong Kim; Yeonjae Kim; Hyunjoo Pai
Journal:  Infect Chemother       Date:  2015-09-30

7.  Rhodoccocus Equi Pneumonia and Paradoxical Immune Reconstitution Inflammatory Syndrome in a Patient with Acquired Immune Deficiency Syndrome (AIDS).

Authors:  Ritika Zijoo; Ahmed Dirweesh; Nigahus Karabulut
Journal:  Am J Case Rep       Date:  2017-01-19

8.  An Adenoviral Vector Based Vaccine for Rhodococcus equi.

Authors:  Carla Giles; Olasumbo Ndi; Mary D Barton; Thiru Vanniasinkam
Journal:  PLoS One       Date:  2016-03-23       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.